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Abstract
Breast cancer (BC) is one of the most common cancers in women. Evidence suggests that genetic variation in antioxidant
enzymes could influence BC risk, but to date the relationship between selenoproteins and BC risk remains unclear. In this
report, a study population including 975 Danish cases and 975 controls matched for age and hormone replacement therapy
(HRT) use was genotyped for five functional single nucleotide polymorphisms (SNPs) in SEPP1, GPX1, GPX4 and the
antioxidant enzyme SOD2 genes. The influence of genetic polymorphisms on breast cancer risk was assessed using
conditional logistic regression. Additionally pre-diagnosis erythrocyte GPx (eGPx) activity was measured in a sub-group of
the population. A 60% reduction in risk of developing overall BC and ductal BC was observed in women who were
homozygous Thr carriers for SEPP1 rs3877899. Additionally, Leu carriers for GPX1 Pro198Leu polymorphism (rs1050450) were
at ,2 fold increased risk of developing a non-ductal BC. Pre-diagnosis eGPx activity was found to depend on genotype for
rs713041 (GPX4), rs3877899 (SEPP1), and rs1050450 (GPX1) and on HRT use. Moreover, depending on genotype and HRT use,
eGPx activity was significantly lower in women who developed BC later in life compared with controls. Furthermore, GPx1
protein levels increased in human breast adenocarcinoma MCF7 cells exposed to b-estradiol and sodium selenite.In
conclusion, our data provide evidence that SNPs in SEPP1 and GPX1 modulate risk of BC and that eGPx activity is modified
by SNPs in SEPP1, GPX4 and GPX1 and by estrogens. Our data thus suggest a role of selenoproteins in BC development.
Citation: Me´plan C, Dragsted LO, Ravn-Haren G, Tjønneland A, Vogel U, et al. (2013) Association between Polymorphisms in Glutathione Peroxidase and
Selenoprotein P Genes, Glutathione Peroxidase Activity, HRT Use and Breast Cancer Risk. PLoS ONE 8(9): e73316. doi:10.1371/journal.pone.0073316
Editor: William B. Coleman, University of North Carolina School of Medicine, United States of America
Received May 7, 2013; Accepted July 18, 2013; Published September 10, 2013
Copyright:  2013 Me´plan et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: CM was supported by Newcastle Healthcare Charity and Biotechnology and Biological Sciences Research Council. The work was supported by the grant
Nutrition Biomics Innovation (NuBI) from The Danish Ministry of Food, Agriculture and Fisheries (J.nr. 3304-FVFP-060696). The funders had no role in study design,
data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: j.e.hesketh@ncl.ac.uk. (JH); ubv@nrcwe.dk (UV)
Introduction
Breast cancer (BC) is a major cause of death in the Western
societies [1]. Inherited BRCA1 and BRCA2 mutations account for a
significant proportion (5–10%) of all breast cancer cases among
white women in the United States [2]. Despite identification of
additional risk factors such as endocrine factors, alcohol and body
mass index [3,4], much of the aetiology of BC remains unclear. It
has been suggested that generation of oxidative stress within breast
tissue may play a role in cancer initiation and development by
causing DNA damage and mutations [5,6]. On the basis of this
hypothesis several studies have investigated whether genetic
polymorphisms in antioxidant enzymes influence either suscepti-
bility to BC or prognosis after diagnosis [7,8,9,10].
One focus of such studies is the genes encoding the selenocys-
teine-containing selenoproteins. Selenoproteins, which carry out
the major biological activity of micronutrient selenium (Se), are
potentially important with respect to BC development because
they protect cells from damaging free radicals [11] and because Se
status, as assessed by serum Se concentration, has been shown to
decrease in BC patients compared with healthy controls [12,13].
Glutathione peroxidases 1 (GPx1) and 4 (GPx4) are well
characterised antioxidant selenoenzymes that detoxify peroxide
radicals and lipid hydroperoxides, respectively [14]. Selenoprotein
P (SePP) exhibits both Se transport and antioxidant functions [15].
These three genes contain common genetic functional polymor-
phisms. Rs1050450 in the GPX1 gene causes an amino acid
change from Pro to Leu at codon 198 [16], with the Leu variants
being less active than its Pro counterpart [17]. Rs713041 in GPX4
affects protein binding to the 39untranslated region (39UTR) of the
mRNA close to an RNA structure (selenocysteine insertion
sequence: SECIS) required for selenoprotein synthesis, although
the nature of the proteins affected has not been defined [18,19,20].
The human SePP gene (SEPP1) contains several functional
polymorphisms, including rs3877899 (Ala234Thr) and rs7579 (a
G/A base change in the 39UTR of SEPP1 mRNA) which affect
plasma and lymphocyte selenoprotein activity in vivo and the
relative proportion of plasma SePP isoforms [21,22]; in addition
both SNPs have also been reported to be associated with colorectal
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and prostate cancer risk [23,24,25]. A small number of functional
variants have been reported in other selenoprotein genes [18] and
in non-selenoprotein genes such as rs4880 in the SOD2 gene
encoding antioxidant manganese superoxide dismutase (MnSOD)
[23,24,26].
To date, the study of selenoprotein genetic variants in relation
to BC risk has been limited. A higher frequency of the Leu variant
of rs1050450 (GPX1) was found in breast tumour DNA compared
to normal tissue, probably due to loss of heterozygosity in the
tumour cells [17]. Two subsequent genetic association studies
failed to identify an association of rs1050450 alone with BC risk
[9,27], but risk was increased in individuals carrying both the Leu
variant in GPX1 and the Ala variant for rs4880 (SOD2) [28]. In
addition, carriage of the Leu variant for rs1050450 in combination
with alcohol intake was associated with higher BC risk [10]. Thus,
it is still unclear whether rs1050450 (GPX1) is a risk factor for BC
[29]. Additionally, an association of rs713041 (GPX4) genotype
and disease prognosis has been reported [26]. However, no genetic
association study of genotype for either rs713041 (GPX4) or for any
SNPs in SEPP1 and BC risk has been carried out so far, although
lymphocyte GPx4 mRNA expression was found to be lower in
breast cancer patients than controls [30].
On the basis of the key role of Selenoprotein P in Se transport
and the functions of GPx1, GPx4 and MnSOD in antioxidant
defence mechanisms, we hypothesize that functional genetic
variants in the corresponding genes influence the susceptibility to
BC. To address this we focussed on known functional SNPs in
these genes and genotyped BC patients and controls from the
Danish prospective ’Diet, Cancer and Health Study’, expanding
on an earlier report [10] by increasing both the number of
participants and the number of genetic variants genotyped, and by
including tumour histology and grade in the analysis.
Materials and Methods
Study design and participants
The subjects for the present study were selected from the
ongoing Danish ‘‘Diet, Cancer and Health’’ cohort study [31].
Between December 1993 and May 1997, 79,729 women aged 50
to 64 years, born in Denmark, living in the Copenhagen or
Aarhus areas and having no previous cancers at this time were
invited to participate in the study. A total of 29,875 women (37%)
accepted the invitation. Cohort members were followed up for
diagnosis of BC from date of entry until either the date of diagnosis
of any cancer (except for non-melanoma skin cancer) using record
linkage to the Danish Cancer Registry up to 2003 or afterwards
with record linkage to the Danish Pathology Databank, date of
death, date of emigration, or April 27th, 2006, whichever came
first. The study group comprised a total of 975 women diagnosed
with BC during a follow-up period until April 27th, 2006 [32,33]
and included 377 previously described postmenopausal women
with breast cancer and matched controls identified at follow-up
until 2003 [10,33,34,35]. For each case with diagnosed BC, one
matched control was selected [32]. The control was cancer-free at
the exact age at diagnosis of the case and was further matched on
age at inclusion into the cohort (half-year intervals) and on use of
hormone replacement therapy (HRT) (current/former/never). For
the cases, tumour classification according to grade (ductal grade 1,
Table 1. Baseline characteristics of the study population.
Variable Cases (N=975) Controls (N=975)
Mean age [95%CI] 57.2 [56.9–57.4] 57.2 [56.9–57.4]
Present smoking (%) 23.1 22.6
Mean Body mass index [95%CI] 25.4 [25.1–25.7] 25.7 [25.2–25.7]
Ductal breast cancer 659 (67.6%)
Grade 1 267 (27.4%)
Grade 2 265 (27.2%)
Grade 3 127 (13%)
Non ductal breast cancer 190 (19.4%)
Tumour Classification Unknown 126 (13%)
HRT use
Never 332 (34%) 332 (34%)
Current 519 (53.2%) 519 (53.2%)
Former 124 (12.8%) 124 (12.8%)
Duration of HRT use in years (among current users) 6.6[6.1–7] 6.9[6.4–7.4]
School education
Low (%) 302 (31%) 341 (35%)
Medium (%) 476 (48.9%) 461 (47.4%)
High (%) 196 (20.1%) 171 (17.6%)
Parous (%) 84.8 87.8
Mean Number of births [95%CI] 1.8 [1.7–1.9] 1.9 [1.9–2]
Mean Age at first birth, years [95%CI] 23.9 [23.6–24.2] 23.5 [23.16–23.7]
Mean alcohol intake in g/day [95%CI] 15.3 [13.7–16.9] 14.1 [12.8–15.5]
Mean selenium intake in mg/day [95%CI] 65.1 [63.1–67.2] 67.8 [65.3–70.3]
doi:10.1371/journal.pone.0073316.t001
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2 or 3) or histology (ductal or non-ductal) was carried out following
criteria recommended by Danish Breast Cancer Cooperative
Group (see [36]). Total Se intake was estimated from food
frequency questionnaire data on dietary intake and use of
supplements [10]. Alcohol intake was calculated from the food
frequency questionnaire data as described previously [32].
The Diet, Cancer and Health study and the present sub-study
were approved by the regional Ethical Committees on Human
Studies in Copenhagen and Aarhus (jr.nr.(KF)11-037/01) and
(jr.nr.(KF)01-045/93), and by the Danish Data Protection Agency.
All participants gave written consent, and the procedure was
approved by the regional Ethical Committees on Human Studies
in Copenhagen and Aarhus.
Blood sampling and storage
30 ml blood were collected from non-fasting participants at the
time of recruitment. Plasma, serum, lymphocytes, and erythrocytes
were isolated and frozen at 220uC within 2 hours. At the end of
the day of collection, all samples were stored in liquid nitrogen.
Erythrocyte GPX activity was determined previously [10].
Genotyping
DNA was isolated from frozen lymphocytes as previously
described [37]. Generally, 100 mg DNA were obtained from 107
lymphocytes. Twenty ng of DNA was genotyped in 5 ul
containing 1x Mastermix (Applied Biosystems), 100 nM probes,
and 900 nM primers and analysed by allelic discrimination on an
ABI7900HT (Applied Biosystems). Controls with known geno-
types were included in each run, and repeated genotyping of 10%
yielded 100% identical genotypes. Genotyping of 377 pairs for
GPX1 Pro198Leu (rs1050450) has been published previously [10]
and extended to the whole cohort. Primers and probes for the
other SNPs were as follows:SOD2 (rs4880) Val16Ala PCR forward;
59-GGC TGT GCT TTC TCG TCT TCA-39, PCR reverse: 59-
CAT GAT CTG CGC GTT GATG-39, probes: T-allele: 59-FAM-
CTC CGG TTT TGGG-MGB-39 and C-allele: 59-VIC-CTC CGG
CTT TGGG-MGB-39; GPX1 (rs1050450) was as previously
Figure 1. Regulation of GPx activity and protein levels. (A) shows the association of rs713041 genotype (GPX4) with pre-diagnosis erythrocyte
GPx (eGPx) activity (Anova, p = 0.015). EGPx activity was lower in TT women who developed BC at a later stage in life. (B) eGPX activity was higher
activity in women using HRT (Anova, p = 0.001). No differences were observed between cases and controls. (C) Combination of HRT use and rs1050450
in GPX1 affects eGPX activity (Anova, main effects of HRT p = 0.004, rs1050450 p= 0.001). HRT use increases eGPX activity in all controls, but not in Leu
carriers who developed BC at a later stage in life. (D) MCF7 cells were exposed to 10nM b-estradiol (b-E2) 6 40nM sodium selenite (Se). Western
blotting of total cell protein revealed as significant increase in GPx1 protein level when cells were treated with b-E2 compared with Se, Se+ b-E2
compared with b-E2 alone or Se alone (Kruskal-Wallis test, effect of treatment p = 0.005; Mann Whitney test* = p,0.05). Values shown are means 6
SEM (n= 3).
doi:10.1371/journal.pone.0073316.g001
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published; PCR forward, 59-TGT GCC CCT ACG CAG GTA
CA-39; PCR reverse, 59-CCC CCG AGA CAG CAG CA-39; C
allele probe, 59-VICCTG TCT CAA GGG CCC AGC TGTG
CTAMRA; and T allele probe, 59-FAMCTG TCT CAA GGG CTC
AGC TGT GCCTTAMRA-39 [38]; GPX4 (rs713041) PCR forward:
59-CCC ACT ATT TCT AGC TCC ACA AGTG-39 and PCR
reverse 59-GTC ATG AGT GCC GGT GGAA-39, probes were
T-allele: 59-FAM-ACG CCC TTG GAGC -MGB-39 and C-allele:
59-VIC-ACG CCC TCG GAGC-MGB-39; SEPP1; rs3877899 was
determined using a premade Taqman assay (Assay 2841533_10
Applied Biosystems) and rs7579 primers were: PCR forward: 5-
‘CAA AAA AGT GAG AAT GAC CTT CAA ACT-3’ and PCR
reverse: 59-ATG CTG GAA ATG AAA TTG TGT CTA GA-39,
probes G-allele: 59-VIC-AAA ATA GGA CAT ACT CCC C-MGB-
39 and A-allele: 59-FAM-AAA TAG AAC ATA CTC CCC AAT
T-MGB-39 (MGB, minor groove binder; FAM, carboxyfluorescein;
TAMRA, carboxytetramethylrhodamine).
Cell culture and preparation of protein extracts
MCF7 human breast adenocarcinoma cells were maintained at
37uC and 5% CO2 in Dulbecco’s Modified Eagles Medium
(DMEM; Gibco, Invitrogen, DMEM-GlutaMAX), supplemented
with 10% foetal bovine Serum (Sigma), 1% Non Essential Amino
Acids (Gibco, Invitrogen) and penicillin/streptomycin (Invitrogen;
100U/500ml media). Cells were treated with Dimethyl sulphoxide
(DMSO, Sigma) (negative control), DMSO + sodium selenite
(7 ng/ml; 40 nM, Sigma) (corresponding to Se-adequate condi-
tions and referred as Se-supplemented in the text by contrast with
the DMEM medium which is poor in Se), b-estradiol (10nM
prepared in DMSO), or a combination of 40 nM sodium selenite
and 10 nM b-estradiol. After 48h treatment, cells were washed
twice in ice-cold PBS, lysed and scraped into130 ml of lysis buffer
(25mM HEPES buffer pH7.6, 3 mM MgCl2, 40 mM KCL, 5%
glycerol, 0.5% NP-40, 2 mM DTT) in the presence of a cocktail of
protease inhibitors (Roche). Cells were sonicated on ice 3 times for
20 sec (Soniprep 150, Sanyo), centrifuged for 5 mins at
13,000 rpm at 4uC and the supernatant collected. Protein
concentration was determined by Bradford assay (Sigma).
Sodium dodecyl sulphate (SDS)-polyacrylamide gel
electrophoresis and Western-blotting
Proteins (40 mg) were separated by electrophoresis on a 10%
SDS-polyacrylamide gel and electro-transferred onto a PVDF
membrane (Roche). Membranes were blocked overnight in PBS
containing 0.05% Tween 20 and 5% dried skimmed milk at 4uC
and then incubated at room temperature for 1 h with polyclonal
anti-polyclonal GPx1 antibody at a 1:500 dilution in PBS
containing 0.05% Tween 20 and 5% dried skimmed milk (Abcam)
or with anti-b-actin (1:5,000 dilution, Sigma). Membranes were
then washed 5 times in PBS-0.05% Tween 20, and incubated for
1 h with HRP-conjugated secondary antibodies, either anti-rabbit
antibody (1:5000 dilution, Sigma) for anti-GPx1 or anti-mouse
(1:5000 dilution, Sigma) for anti-b-actin. After a further 5 washes
of the membranes, immuno-detection was carried out using a
chemiluminescence kit (GE Healthcare) on Amersham Hyper-
filmTM ECL (GE Healthcare). Band intensity was quantified
using UVIband software (Uvitec, UK).
Statistical analysis
To estimate the association between individual SNPs and breast
cancer, we calculated odds ratios (OR) and 95% confidence
intervals (95% CI) using conditional logistic regression analysis and
STATA 11.0 statistical software. Estimates were adjusted for age,
body mass index (BMI), smoking, fruit and vegetable intake,
alcohol and tobacco consumption, HRT use, number and year of
childbirths and Se intake estimated from a food frequency
questionnaire. Genotypes were evaluated using indicator variables
with the common homozygote as reference. Two models were
tested: a recessive model, in which each genotype was compared
with the homozygote for the frequent allele to assess the effect of
each genotype on the risk of breast cancer and a dominant model
in which heterozygotes and homozygotes for the rare allele were
pooled together and compared with the homozygote for the
frequent allele to assess the effect of the presence of at least one
rare allele on breast cancer risk. Conditional logistic regression of
two-loci interaction was performed for selected SNPs when either
(i) the SNPs showed a main effect or (ii) multivariate conditional
logistic regression suggested an interaction and when in addition,
the likelihood ratio test showed significant interactions (P#0.05).
ORs and 95% CI are presented with reference to the double
homozygous genotype for the most frequent allele.
Table 2. Effect of selenoprotein SNPs on breast cancer risk.
GENE
(polymorphism) Genotype
Cases/
Controls
OR
(95% CI) p-value
SOD2
(rs4880)
Total 939/958
CC 226/227 1 [-]
CT 485/494 1.09 [0.83–1.45] 0.53
TT 228/237 0.96 [0.69–1.34] 0.813
CT+TT 713/731 1.05 [0.8–1.38] 0.701
GPX1
(rs1050450)
Total 933/959
CC 465/503 1 [-]
CT 396/370 1.03 [0.81–1.32] 0.789
TT 72/86 0.83 [0.54–1.28] 0.393
CT+TT 468/456 0.99 [0.79–1.25] 0.96
GPX4
(rs713041)
Total 939/960
CC 319/335 1 [-]
CT 438/430 1.16 [0.9–1.49] 0.241
TT 182/195 0.92 [0.66–1.28] 0.63
CT+TT 620/625 1.09 [0.86–1.38] 0.459
SEPP1
(rs3877899)
Total 937/959
GG 586/594 1 [-]
GA 321/317 1 [0.78–1.28] 0.984
AA 30/48 0.39 [0.2–0.75] 0.005
GA+AA 351/365 0.91 [0.72–1.15] 0.436
SEPP1
(rs7579)
Total 937/957
GG 455/436 1 [-]
GA 396/420 0.86 [0.68–1.09] 0.206
AA 86/101 0.75 [0.5–1.13] 0.163
GA+AA 482/521 0.84 [0.67–1.05] 0.125
Adjusted values were analysed by conditional logistic regression. Odd ratios
(95% confidence interval) and p-values are presented together with the number
of cases and controls for each genotype. Significant results are presented in
bold and italic.
doi:10.1371/journal.pone.0073316.t002
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Results
Genotype, tumour classification and disease risk
The overall study population included 975 cases and 975
controls matched for age and hormone replacement therapy
(HRT). Baseline characteristics of women diagnosed with breast
cancer and their matched controls are presented in Table 1 (means
and 95% confidence interval) and findings regarding all the
included risk factors have been reported previously [32,33,34].
Genotype frequencies for rs4880 (SOD2), rs7579 and rs3877899
(SEPP1), rs713041 (GPX4) and rs1050450 (GPX1) are shown in
Table 2. With the exception of rs713041, the genotype distribu-
tions of the studied polymorphisms were in Hardy-Weinberg
equilibrium (HWE) among the controls. The failure of rs713041 to
conform to HWE may reflects the fact that controls were matched
for secondary criteria including HRT and thus do not represent
the general population [39]. To address the hypothesis that known
functional variants in selenoprotein genes affect BC risk and
tumour grade or histology the association of the individual SNPs
with BC risk was assessed by conditional logistic regression using
recessive and dominant models and adjusted as described in the
method section. Genotype for SEPP1 Ala234Thr (rs3877899) was
significantly associated with risk of breast cancer with the
homozygous AA genotype (Thr/Thr) having a lower risk of breast
cancer (OR 0.39, 95%CI 0.2–0.75, p = 0.005, Table 2).
BC cases were classified as having either ductal tumours (659)
with 267 being grade 1, 265 grade 2 and 127 grade 3 or non-
ductal tumours (190 cases); 126 cases had no tumour classification
at the time of follow up. Stratifying the genotyping data according
to these diagnostic criteria allowed analysis of the association of
genotype with risk of particular tumour grade or histology
(Table 3). Rs3877899 (SEPP1) was associated with risk of ductal
tumours with homozygous AA having a lower disease risk (OR
0.48, 95% CI 0.26–0.88, p = 0.017). In contrast, rs3877899 was
not associated with risk of a non-ductal tumour; however, women
homozygous TT for rs1050450 (GPX1, Leu variant) had an
increased risk of having a non-ductal tumour (1.88 [1.08–3.28],
p = 0.027) but it should be noted that there were few individuals
with this genotype. In addition, Leu carriers (rs1050450, GPX1)
had an increased risk of having a grade 3 ductal tumour compared
with grade 1 and 2 (OR 2.64, 95%CI 1.13–6.16 p= 0.025). None
of the other SNPs were associated with BC or BC subtypes.
Selenoprotein P supplies Se to non-hepatic tissues [40] to
support synthesis of other selenoproteins and therefore we tested
Figure 2. Model of the regulation of GPx1 in breast cells by selenium and estrogens. Our hypothesis is that GPx1 concentration in breast
cells is controlled by (i) factors that affect Se bioavailability (Se supply and polymorphisms in SEPP1) or the selenoprotein hierarchy (e.g. rs713041 in
GPX4), (ii) estrogen levels and estrogen receptor status of breast tumour cells, (iii) the Pro198Leu polymorphism (rs1050450) in GPX1. Combinations of
these factors contributing to low GPx1 activity/levels will result in lower capacity to respond to reactive oxygen species (ROS), favouring
accumulation of oxidative damage and promoting tumour progression. In contrast maintaining high GPx1 activity has the potential to delay tumour
progression.
doi:10.1371/journal.pone.0073316.g002
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the hypothesis that SEPP1 variants interacted with SNPs in other
selenoprotein genes to modify BC risk by first carrying out a
multivariate logistic regression including all 5 SNPs. Using a
dominant model stratification of the genotyping data according to
tumour grade or histology revealed an interaction between
rs3877899 (SEPP1) and rs1050450 (GPX1), with women who were
heterozygous for both rs1050450 (CT) and rs3877899 (GA) being
at increased risk of developing non-ductal breast cancer
(OR=2.94, 95%CI 1.35–6.37, p = 0.006, Table 4). Similar results
were obtained using a dominant model, with women carrying both
rs1050450 (CT+ TT) and rs3877899 (GA +AA) having an
increased risk of developing non-ductal breast cancer
(OR=2.59, 95%CI= 1.28–5.22, p = 0.008, Table 4). In addition,
we observed a genetic interaction between rs1050450 (GPX1) and
rs7579 (SEPP1), with carriers of both rs1050450 (CT+TT) and
rs7579 (GA+AA) genotype having an increased risk of a grade 3
tumour compared with grades 1 and 2 (OR=2.63,
95%CI= 1.63–6.71, p = 0.042, Table 4), indicating that the
association of rs1050450 genotype with the risk of grade 3 tumour
was modified by genotype for rs7579 in SEPP1. Although carriage
of only one copy of the Leu allele (GPX1) showed no statistical
effect on disease risk, the influence of heterozygosity for rs1050450
was modified by both SEPP1 SNPs, with heterozygosity for both
rs1050450 and rs3877899 increasing the risk (OR=3.36, 95%CI
1.43–7.94, p = 0.006, Table 4) but heterozygosity for both
rs1050450 and rs7579 reducing the risk (OR=0.34, CI 0.15–
0.77, p = 0.01, Table 4). It was not possible to analyse effects of
interactions of these other variants with being homozygous for the
Leu allele of rs1050450 because of the small numbers of
individuals with those combined genotypes. However, taken
together the observation that being homozygous for the
rs1050450 Leu allele significantly increases risk of a non-ductal
tumour combined with the significant effects of heterozygosity for
rs1050450 and rs3877899 on risk of the same diagnosis indicates
that carriage of at least a minor Leu allele is associated with
increased risk of such a tumour.
Table 3. Effect of selenoprotein SNPs on breast cancer risk after stratification of data according to tumourgrade and histology.
Ductal vs control Non-ductal vs control
GENE (polymorphism) Genotype OR (95% CI) p-value OR (95% CI) p-value
SOD2 (rs4880) CC 1[-] 1[-]
CT 0.98 [0.74–1.29] 0.88 1.13 [0.72–1.77] 0.604
TT 0.99 [0.72–1.36] 0.937 1.18 [0.7–1.99] 0.525
GPX1 (rs1050450) CC 1[-] 1[-]
CT 1.16 [0.92–1.47] 0.206 1.13 [0.77–1.66] 0.545
TT 0.73 [0.47–1.14] 0.166 1.88 [1.08–3.28] 0.027
GPX4 (rs713041) CC 1[-] 1[-]
CT 1.16 [0.9–1.5] 0.237 1.02 [0.68–1.52] 0.935
TT 0.91 [0.66–1.25] 0.552 1.03 [0.63–1.67] 0.911
SEPP1 (rs3877899) GG 1[-] 1[-]
GA 0.98 [0.77–1.24] 0.849 0.92 [0.62–1.35] 0.656
AA 0.48 [0.26–0.88] 0.017 0.89 [0.4–1.99] 0.785
SEPP1 (rs7579) GG 1[-] 1[-]
GA 0.91 [0.72–1.15] 0.42 1.17 [0.81–1.69] 0.404
AA 0.86 [0.58–1.28] 0.454 0.65 [0.32–1.33] 0.235
Adjusted values were analysed by conditional logistic regression. Odd ratios (95% confidence interval) and p-values are presented for each genotype. Significant results
are presented in bold and italic.
doi:10.1371/journal.pone.0073316.t003
Table 4. Significant SNP-SNP interactions in relation to breast cancer risk and tumour grades.
SNP-SNP interaction
Genotype
combination
Compared
groups OR [95% CI]
p-
value
rs1050450 (GPX1) *rs7579 (SEPP1) (CT+TT) * (GA+AA) ductal grade 3 (43/39)/ductal grade 1 &2(127/154) 2.63 [1.63–6.71] 0.042
rs1050450 (GPX1) * rs38773899 (SEPP1) (CT) * (GA) non-ductal (31/63)/ductal(91/193) 2.94 [1.35–6.37] 0.006
rs1050450 (GPX1) * rs38773899 (SEPP1) (CT+ TT) * (GA +AA) non-ductal(42/63)/ductal(110/193) 2.59 [1.28–5.22] 0.008
rs1050450 (GPX1) * rs38773899 (SEPP1) (CT)*(GA) non-ductal(31/63)/control (166/306) 3.36 [1.43–7.94] 0.006
rs1050450 (GPX1) * rs38773899 (SEPP1) (CT+TT)*(GA+AA) non-ductal (42/63)/control (121/306) 2.77[1.37–6.2] 0.006
rs1050450 (GPX1) * rs7579 (SEPP1) (CT)*(GA) non-ductal (23/35)/control(172/231) 0.34 [0.15–0.77] 0.01
Only significant interactions between two loci, as identified by logistic regression, are presented. Loci are identified by rs number and OR values with 95% CI are shown
as well as p-values. Compared group are indicated with the ratio corresponding to the number of women with the combined genotypes as indicated in the adjacent left
column/number of women double homozygous for the reference most frequent allele.
doi:10.1371/journal.pone.0073316.t004
Selenoprotein SNPs,GPx1 Activity and Breast Cancer
PLOS ONE | www.plosone.org 6 September 2013 | Volume 8 | Issue 9 | e73316
Genotype, GPx activity and disease risk
Erythrocyte GPx activity (eGPx), which largely reflects GPx1
expression, is influenced by rs1050450 (GPX1) genotype [41,42].
Pre-diagnostic eGPX activity was available for 377 matched pairs
in the study population and since selenoproteins essentially
compete for available Se during synthesis, we tested the hypothesis
that SNPs in other selenoprotein genes modulate eGPx activity.
Univariate analysis revealed a main effect of rs713041 in GPX4 on
eGPx activity (p = 0.015), with CC carriers having lower activity
than CT or TT carriers (Figure 1A). In addition, TT carriers for
rs713041 who later develop BC exhibited a significantly lower
eGPx compared with the ones who did not develop the disease
(p,0.001). This effect did not reflect a difference between controls
and cases in eGPx activity (data not shown, p= 0.257). These
effects of the GPX4 variant on eGPx activity are compatible with
previous work showing that rs713041 affects blood cell GPx1
protein levels, probably by affecting the ability of the GPX4mRNA
to compete in the selenoprotein synthesis hierarchy [19].
In addition, current HRT users at the time of eGPx
measurement exhibited higher activity than women who had
either never or previously used HRT (ANOVA, main effect HRT
p=0.001, Figure 1B) independently of the BC status. However
when genotype for rs1050450 was taken into account, we observed
a main effect of HRT (ANOVA, p= 0.004) and of rs1050450
(ANOVA, p=0.001) in the prediction of eGPx activity level.
Current HRT users (both cases and controls) who were Pro or
Pro/Leu carriers showed higher eGPx activity compared with
never or former HRT users (Figure 1C). On the contrary, eGPx
activity was increased in homozygous Leu carrier controls who
were current HRT users but not among Leu carriers who at a later
stage in their life developed breast cancer (p = 0.045; Figure 1C).
The observed effects of HRT on eGPx activity suggested that
GPx1 expression is regulated by estrogen. To test this hypothesis,
MCF7 cells were treated with 10 nM b-estradiol for 48 h in the
presence or absence of sodium selenite (40 nM) and GPx1 protein
level (relative to b-actin control) assessed by western-blot analysis
(Figure 1D). GPx1 protein levels were very low in cells grown in
standard medium but supplementation with sodium selenite
resulted in a 1.98 (60.82) fold increase of GPx1 protein after
48h. b-estradiol treatment resulted in a larger increase of GPx1
protein level (5.33 (60.83) fold) and this effect was additive in the
presence of the combination b-estradiol and sodium selenite (7.84
(60.85) fold).
Discussion
The aetiology of breast cancer is only partially understood but
oxidative stress-induced DNA damage has been suggested to be
critical for the initiation and progression of the disease [5,43].
Several selenoproteins are known to have antioxidant functions
[11] and the present work provides evidence that genetic variants
in SEPP1 and GPX1 affect BC risk.
A dramatic 60% decrease in risk of developing total or ductal
BC was observed in homozygous Thr carriers for rs3877899
(SEPP1) compared with Ala carriers. Since there was no observed
effect of this variant on risk of a non-ductal tumour it is likely that
the decreased risk of developing total BC due to this SNP is largely
due to an effect on developing a ductal tumour. To our knowledge,
this is the first evidence that this SNP influences BC risk. SePP has
a major role in Se transport [40] and previous data have indicated
that both rs3877899 and rs7579 in SEPP1 modulate selenoprotein
concentrations and activities in the plasma, erythrocytes and
lymphocytes and plasma SePP isoform pattern [21,22], suggesting
that these polymorphisms can affect Se delivery to tissues. The
effects of genotype for rs3877899 (SEPP1) on BC risk suggest that
altered Se supply to the breast tissue could contribute to BC
development, potentially by affecting local expression of other
selenoproteins.
Leu carriers for rs1050450 (Pro198Leu) in GPX1 were shown to
have a 1.9-fold increased risk of developing non-ductal breast
cancer. In addition, carriers of this variant were also 2.6 fold more
likely to have a grade 3 ductal tumour compared to a grade 1 or 2
tumour. Since enzymatic assays have previously shown that the
Leu protein variant is less active than the Pro counterpart [16,17]
we propose that high GPx1 activity is required to counterbalance
the levels of ROS and related damage occurring during initiation
or progression of the disease (Figure 2).
Although a meta-analysis [44] indicated an association between
BC risk and genotype for Pro198Leu (GPX1) in premenopausal
women, a genome-wide association study (GWAs) approach failed
to find any statistically significant associations for either rs1050450
(GPX1) or rs4880 (SOD2) [44,45,46]. In addition, in the GWAs
rs3877899 (SEPP1) was not identified as being associated with BC
risk, nor was it apparently linked to SNPs showing an association
[46]. It is not clear why the present analysis revealed effects that
were not observed from this GWAs carried out on a US
population [44,45,46] but since generally Se intake is higher in
US than in Europe [47] it is possible that effects of genotype for
rs1050450 (GPX1) were revealed in the Danish cohort because of a
lower, sub-optimal, Se intake. An estimate of Se intake was
calculated on the basis of food questionnaires [48] for the present
cohort (67.8 mg/day [65.3–70.3] in controls and 65.1 mg/day
[63.1–67.2] in cases, Table 1) and indeed this suggests that their Se
intake is lower than that found in the US (.100 mg/day). Thus, it
is possible that the observed effects of the variants are particularly
relevant to populations where Se intake in low. Interestingly, a
GWAs carried out in UK identified a locus located close to the
SEPP1 gene to be associated with BC risk [49] but it is not known
if it is linked to either rs3877899 or rs7579. In addition, the present
study population was well characterised in terms of disease stage
and HRT, and this may reduce confounding of genetic effects by
such factors. Finally, alcohol intake is generally high amongst
Danish women and this may modify the association of BC with
SNPs in antioxidant enzymes, as observed previously [7,8,9,10].
The mean alcohol intake in the present study (estimated from food
frequency questionnaires) was 14.1 [12.8–15.5] g/day for controls
and 15.3 [13.7–16.9] g/day for cases respectively (Table 1),
considerably higher than reported intakes of 5–6 g/day or lower
in the US [50].
Interestingly, rs3877899 (SEPP1) genotype has previously been
found to be associated with risk of prostate cancer, another
hormone-dependent cancer [23]. Although the strongest and most
robust risk factors for BC are increased female hormone levels
[31,51], the roles of hormones in BC aetiology are complex; on
one hand the production of ROS through redox cycling of the
catechol estrogens has been suggested to contribute to breast
carcinogenesis by increasing DNA damage, and on the other
hand, estrogens have been shown to upregulate antioxidant
enzymes (MnSOD and glutathione peroxidases) via the NFkB
pathway in animal models [52,53,54]. Notably blood Se levels
vary through the menstrual cycle with the highest levels coinciding
with the peak of estrogen levels [55]. Since SePP1 accounts for the
majority of blood Se this suggests that SePP1 levels, and thus Se
supply, may respond to estrogen.
eGPx activity has been reported previously to be greater in
controls than in breast cancer cases [10]. In the additional work
presented here on the same data a more complex relationship
between genotype for rs1050450 (GPX1), eGPx activity, HRT use
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and BC risk was revealed. eGPx activity was higher in women
currently using HRT compared with former/never users of HRT,
suggesting that HRT use raised eGPX activity. This hypothesis is
supported by the effect of b-estradiol in increasing both GPx1
protein levels (Figure 1D) and GPx activity in MCF7 cells [43].
The present results indicate that both Se supply and b-estradiol
regulate breast cell eGPx activity. In addition, a lower eGPx
activity in BC cases compared with controls was only found in
homozygous Leu carriers who were current HRT users, suggesting
that HRT failed to stimulate an increase in eGPx activity in
women who later developed cancer. This could indicate that either
1) low GPx activity predisposes these women to oxidative damage
and cancer development, 2) these women require more Se to raise
their GPx activity to respond to HRT or 3) Se is diverted towards
other tissues (e.g. breast) as an early sign of oxidative stress. The
latter explanation is compatible with the observation that estradiol
affects Sepp1 and GPx1 mRNA expression and Se tissue
distribution in ovarectomized female rats [56].
eGPx activity corresponds mainly to GPx1 activity. Baseline
measurements of eGPx activity revealed that rs713041(GPX4) also
associates with eGPx activity and is compatible with findings that
rs713041 affects both the response of lymphocyte GPx1 levels to
Se supplementation and the relative binding of proteins to the
GPX1 and GPX4 39UTR [19]. Since protein binding to the SECIS
element within the 39UTR is critical to controlling the relative
synthesis of different selenoproteins [18], the present results
suggest that women with CC genotype for rs713041 channel Se
towards GPx4 synthesis and lowers Se availability for GPx1
synthesis; in contrast, for CT and TT carriers GPx4 competes less
for Se and more Se is therefore available for GPx1 synthesis.
Overall, the data suggest a model of GPx1 regulation in which
breast GPX1 expression depends on the combination of dietary Se
intake, delivery/distribution of Se (influenced by SNPs in SEPP1),
factors altering the selenoprotein hierarchy (e.g. SNP in GPX4
gene), and hormonal regulation of GPx1 expression. The effect on
GPx1 expression is further modulated by the presence of the
Pro198Leu SNP (rs1050450) altering enzyme activity. We
hypothesise that the capacity of an individual to deliver Se to
the breast tissue and generate high or low GPx1 activity ultimately
determines the susceptibility of their breast tissue to oxidative
damage and carcinogenesis. The data indicate that individuals
who carry the Leu allele and who have low eGPx activity when
using HRT are at increased risk of subsequently developing BC
(Figure 2).
Our results suggest that there is a complex interplay between
estrogen and Se-dependent antioxidant activity which may play a
role in breast carcinogenesis. Genotype for both rs1050450 (GPX1)
and rs3877899 (SEPP1) were found to modulate BC risk and grade
in a Danish cohort in which Se intake was previously estimated to
be low [42]. Previously genotype for rs713041 (GPX4) has been
reported to be associated with prognosis after diagnosis of breast
cancer [26]. The present data show that rs713041 also modulates
eGPx activity, with TT carriers who later develop BC exhibiting a
significantly lower eGPx compared with the ones who did not
develop the disease. Thus, we propose that genotypes for both
rs713041 (GPX4) and rs1050450 (GPX1) influence breast GPx1
activity and that this impinges on BC risk and grade. In
conclusion, the our data provide evidence that SNPs in SEPP1
and GPX1 modulate risk of BC and that eGPx activity is modified
by SNPs in SEPP1, GPX4 and GPX1 and by estrogens, thus
suggesting a role of selenoproteins in BC development. Although
earlier work has suggested that antioxidant enzyme SNP genotypes
are not useful in screening for human disease [57], the present
findings lead us to speculate that the combination of selenoprotein
genotype and eGPx activity may be a useful biomarker of BC risk
in populations where Se intake is relatively low, for example as has
been found in European populations [47].
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